Savara Inc. (SVRA)

4.7050 +0.0250 (+0.53%) At close: 04:00PM EDT

Savara Inc.

1717 Langhorne Newtown Road
Suite 300
Langhorne, PA 19047
United States
(512) 614-1848
https://www.savarapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 37

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Matthew Pauls J.D., M.B.A.	Chairman & CEO	970k	N/A	1971
Mr. David L. Lowrance CPA	CFO, Chief Administrative Officer & Secretary	667.4k	N/A	1968
Mr. Scott L. Wilhoit	Executive Vice President of Global Commercial	N/A	N/A	1963
Dr. Brian Robinson M.D.	Senior VP of Global Medical Affairs	N/A	N/A	N/A
Dr. Yasmine Wasfi M.D., Ph.D.	Senior VP & Head of Clinical Development	N/A	N/A	N/A
Dr. Siddharth J. Advant Ph.D.	Executive Vice President of Global Technical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

Corporate governance

Savara Inc.’s ISS governance QualityScore as of 1 May 2024 is 4. The pillar scores are Audit: 4; Board: 6; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.